RT Journal Article
T1 Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.
A1 Provencio, Mariano
A1 Cobo, Manuel
A1 Rodriguez-Abreu, Delvys
A1 Calvo, Virginia
A1 Carcereny, Enric
A1 Cantero, Alexandra
A1 Bernabe, Reyes
A1 Benitez, Gretel
A1 Castro, Rafael López
A1 Massuti, Bartomeu
A1 Del Barco, Edel
A1 García Campelo, Rosario
A1 Guirado, Maria
A1 Camps, Carlos
A1 Ortega, Ana Laura
A1 Gonzalez-Larriba, Jose Luis
A1 Sanchez, Alfredo
A1 Casal, Joaquín
A1 Sala, M Angeles
A1 Juan-Vidal, Oscar
A1 Bosch-Barrera, Joaquim
A1 Oramas, Juana
A1 Domine, Manuel
A1 Trigo, Jose Manuel
A1 Blanco, Remei
A1 Calzas, Julia
A1 Morilla, Idoia
A1 Padilla, Airam
A1 Pimentao, Joao
A1 Sousa, Pedro A
A1 Torrente, Maria
K1 Biomarkers
K1 Metastatic lung cancer
K1 Targeted therapies
K1 Testing
AB The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immunotherapy itself. This work aims to study the situation of biomarker testing in Spain. The Thoracic Tumours Registry (TTR) is an observational, prospective, registry-based study that included patients diagnosed with lung cancer and other thoracic tumours, from September 2016 to 2020. This TTR study was sponsored by the Spanish Lung Cancer Group (GECP) Foundation, an independent, scientific, multidisciplinary oncology society that coordinates more than 550 experts and 182 hospitals across the Spanish territory. Nine thousand two hundred thirty-nine patients diagnosed with stage IV non-small cell lung cancer (NSCLC) between 2106 and 2020 were analysed. 7,467 (80.8%) were non-squamous and 1,772 (19.2%) were squamous. Tumour marker testing was performed in 85.0% of patients with non-squamous tumours vs 56.3% in those with squamous tumours (p-value  Despite the lack of a national project and standard protocol in Spain that regulates the determination of biomarkers, the situation is similar to other European countries. Given the growing number of different determinations and their high positivity, national strategies are urgently needed to implement next-generation sequencing (NGS) in an integrated and cost-effective way in lung cancer.
PB BioMed Central Ltd.
YR 2022
FD 2022-06-27
LK http://hdl.handle.net/10668/20282
UL http://hdl.handle.net/10668/20282
LA en
NO Provencio M, Cobo M, Rodriguez-Abreu D, Calvo V, Carcereny E, Cantero A, et al. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics. BMC Cancer. 2022 Jul 5;22(1):732
DS RISalud
RD Apr 17, 2025